Drugs / VLA2001
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04671017 | Dec 2020 → Feb 2021 | COVID-19 | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05298644 | Oct 2022 → Jul 2023 | COVID-19 | Valneva Austria GmbH | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05364242 | May → Sep 2022 | Orthocoronavirinae infectious disease | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05545683 | Dec 2022 → Mar 2023 | COVID-19 | Centro de Estudios en Infectogía Pediatrica | Withdrawn | No outcome recorded |
| Phase 3 | NCT04956224 | Aug → Nov 2021 | COVID-19 | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 3 | NCT04864561 | Apr → Jul 2021 | COVID-19 | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLA2001 | “VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine” NCT05545683 ↗ |
| Known as | Valneva COVID-19 vaccine | “The Valneva COVID-19 vaccine (VLA2001; Valneva Austria, Vienna, Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine.” PMID 36075233 ↗ Sep 2022 |
| Modality | Vaccine | “whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide” NCT04671017 ↗ |
| Route | Intramuscular | “All participants will received a total of two vaccinations intramuscularly, on day 1 and day 22.” NCT04671017 ↗ |